COMP <GO>
LGND vs RYTM // ENTERPRISE SCALE & MARKET CAP
Ligand Pharmaceuticals Incorporated (NASDAQ) VS. Rhythm Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: LGND 9
— RYTM 2
▲ ENTERPRISE SCALE & MARKET CAP LEADER: LGND
LAST: $307.02 (-4.87%) • MKT CAP: $6.43B
market-cap
$6.43B
LAST: $93.44 (+0.94%) • MKT CAP: $6.37B
market-cap
$6.37B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LGND VS. RYTM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LGND | RYTM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 89.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.00% | -29.60% | +32.60 | LGND | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.77% | -1.82% | +2.59 | LGND | /fcf-yield <GO> |
| Operating Margin | 15.30% | -60.00% | +75.30 | LGND | /operating-margins <GO> |
| Net Profit Margin | 46.40% | -0.10% | +46.50 | LGND | /net-margins <GO> |
| Revenue Growth (YoY) | 60.40% | 45.80% | +14.60 | LGND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.40 | 14.33 | -5.93 | RYTM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | LGND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.9 | 50.0 | +11.90 | LGND | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.96 | +0.11 | LGND | /macro-sensitivity <GO> |
| Forward P/E Multiple | 42.7x | 33.0x | +9.70 | RYTM | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $6.43B | $6.37B | $60.6M | LGND | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LGND REV | RYTM REV | LGND GROSS % | RYTM GROSS % | LGND FCF | RYTM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $268.1M | $189.8M | — | 89.7% | $48.9M | -$116.6M |
| FY 2024 | $167.1M | $130.1M | — | 89.7% | $95.2M | -$113.9M |
| FY 2023 | $131.3M | $77.4M | — | — | $43.7M | -$139.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LGND // BETA 1.07
RYTM // BETA 0.96